Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
NCT00073749
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
79
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, B-Cell
Interventions
DRUG:
Inotuzumab ozogamicin [CMC-544]
Sponsor
Pfizer